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Abstract 
 
An early step in pancreas development is marked by the expression of the Pdx1 transcription 
factor within the pancreatic endoderm where it is required for the specification of all endocrine 
cell types.  Subsequently, Pdx1 expression becomes restricted to the β-cell lineage where it 
plays a central role in β-cell function.  This pivotal role of Pdx1 at various stages of pancreas 
development makes it an attractive target to enhance pancreatic β-cell differentiation and 
increase β-cell function.  In this study, we used a newly generated zebrafish reporter to screen 
over 8,000 small molecules for modulators of pdx1 expression.  We found four hit compounds 
and validated their efficacy at different stages of pancreas development.  Valproic acid (VPA), 
a HDAC inhibitor, induces pancreatic endoderm formation, while inhibition of TGF-β signaling 
leads to the transdifferentiation of -cells to β-cells.  HC Toxin, another HDAC inhibitor, 
enhances β-cell function in primary mouse and human islets.  Thus, using a whole-organism 
screening strategy, this study identified new pdx1 expression modulators which can be used to 























Diabetes mellitus is foreseen to be the 7th leading cause of death in 2030 (according to the 
World Health Organization), warranting an urgent need to identify new therapeutics.  During 
the development of type 2 diabetes, β-cells increase insulin production to compensate for 
insulin resistance.  However, type 2 diabetes only manifests itself once β-cell failure and death 
occur, resulting in reduced amounts of circulating insulin (Bonner-Weir 2004, 2013). 
The transcription factor pancreatic and duodenal homeobox 1 (Pdx1), is a key player in 
pancreas development and β-cell function/maturation.  In vertebrates, Pdx1 is first expressed in 
the whole pancreatic endoderm, and its importance in early pancreas development has been 
demonstrated by the global knockout of Pdx1 which leads to pancreas agenesis and lethality 
(Jonsson et al. 1994; Offield et al. 1996; Hale et al. 2005).  During development, an increase in 
PDX1 levels in endocrine progenitors is indispensable for their differentiation into β-cells 
(Bernardo et al. 2008).  In addition, forced expression of PDX1 in endocrine progenitors leads 
to their conversion into β-cells at the expense of -cells (Yang et al. 2011).  In adult mice, 
PDX1 is specifically expressed in β-cells, and the deletion of Pdx1 from mature β-cells leads 
to their dedifferentiation and loss of function (Ahlgren et al. 1998; Gao et al. 2014).  In addition, 
Pdx1 haploinsufficiency in mice leads to impaired β-cell function and apoptosis (Johnson et al. 
2003).  In mature β-cells, PDX1 regulates the expression of a whole network of genes important 
for β-cell function, including insulin and glucokinase (Ahlgren et al. 1998; Hani et al. 1999; 
Gao et al. 2014).  Notably, and accordingly, MODY4 (Maturity onset of diabetes of the young 
4) is caused by mutations in PDX1 which lead to diabetes due to impaired β-cell function 
(Fajans et al. 2001).  Together, these data point to a central role for PDX1 in pancreas and β-
cell development.  Therefore, the possibility to regulate the network responsible for β-cell 
development by modulating a single transcription factor makes PDX1 an interesting target for 
small molecule screens.   
To identify molecular pathways regulating pdx1 expression, we used the zebrafish, an animal 
model ideally suited for in vivo small molecule screens (Gut et al. 2017); developed novel 
reporters, and used them to screen 8,256 structurally diverse compounds and subsequently 
investigated the top hits.  Besides known modulators of pdx1 expression, we identified four 
interesting compounds which can be used to modulate pancreatic endoderm formation, β-cell 
specification and/or β-cell function.  Notably, VPA treatment increased the formation of the 
pancreatic endoderm, while inhibition of TGF- β signaling led to the transdifferentiation of -
cells to β-cells.  Furthermore, we tested HC Toxin on human islets and in an iPSC-derived 
pancreatic β-cell differentiation model, and found that it induces β-cell function including 
enhanced expression of mature β-cell marker genes and enhanced insulin secretion. 
 
Materials and methods 
 
Zebrafish husbandry and strains 
All zebrafish husbandry was performed under standard conditions in accordance with 
institutional (MPG) and national ethical and animal welfare guidelines.  Embryos were staged 
by hours post fertilization (hpf) at 28.5°C (Kimmel et al. 1995).  The following lines were used: 
Tg(fabp10a:EGFP)as3 (Her, Yeh, and Wu 2003), Tg(ins:Kaede)jh6 (Pisharath et al. 2007), 



















al. 2013) abbreviated Tg(ins:H2B-GFP;ins:DsRed), Tg(pck1:Luciferase)s952 (Gut et al. 2013), 
TgBAC(neuroD:EGFP)nl1 (Obholzer et al. 2008), pdx1sa280 (Kimmel et al. 2015), insulinbns102 
(Mullapudi et al. 2018), Tg(insulin:loxP:mCherrySTOP:loxP:H2B-GFP; cryaa:Cerulean)s934 
(Hesselson et al. 2011), Tg(sox17:GFP)s870 (Sakaguchi et al. 2006), 
Tg(Tp1bglob:H2BmCherry)S939 (Ninov et al. 2012), Tg(ubb:loxP:CFP:loxP:H2B-mCherry)jh63 
(Wang et al. 2015), TgBAC(arxa:Cre)bns250 (this study), TgBAC(pdx1:EGFP)bns13 (this study), 
TgBAC(pdx1:luciferase2)bns17 (this study) and Tg(ins:loxP-Eco.NfsB-mCherry-loxP-
luciferase)bns152 (this study), abbreviated as Tg(ins:mCherry). 
 
Human islet isolation 
Islets were isolated from pancreata procured within the Nordic Network for Clinical Islet 
Transplantation as previously described (Goto et al. 2004).  Consent for organ donation (for 
clinical transplantation and for use in research) was obtained via an online database 
(https://www.socialstyrelsen.se/donationsregistret/anmalan) or verbally from the deceased’s 
next of kin by the attending physician.  The consent was documented in the medical records of 
the deceased in accordance with Swedish law and as approved by the Regional Ethics 
Committee (Dnr 2009/371/2).  The experiments using human islets in this study were approved 
by the Regional Ethics Committee in Uppsala (Dnr 2015/444).    
 
hiPSC culture 
Human iPSC lines (iXM001 and BIH004) were maintained on Geltrex-coated (Invitrogen) 
plates in home-made E8 media, as reported in (Chen et al. 2011) under hypoxic conditions.  The 
medium was changed daily and cells were passaged every ∼3 days as cell clumps or single cells 
using 0.5 mM EDTA (Invitrogen) or Accutase (Invitrogen), respectively.  Medium was 
supplemented with 10 μM Rho-associated protein kinase (ROCK) inhibitor Y-27632 (Sigma) 
when iPSCs were thawed or passaged as single cells. 
 
Differentiation of pluripotent iPSCs into pancreatic β-like cells  
Differentiation was carried out following a 21-day protocol described in Russ et al. (2015).  
Briefly, iPSCs were dissociated using Accutase and seeded at a density of 5.5 x106 cells per 
well in ultra-low attachment 6-well plates (Thermo Fisher Scientific) in 5.5 ml E8-home 
medium supplemented with 10 μM ROCK inhibitor, 10 ng/ml Activin A (R&D Systems) and 
10 ng/ml Heregulin-b1 (Peprotech).  Plates were placed on an orbital shaker at 100 rpm to 
induce sphere formation at 37°C in a humidified atmosphere containing 5% CO2.   
To induce definitive endoderm differentiation, cell clusters were collected after 36 hrs in a 50-
ml falcon tube, washed with PBS and re-suspended in d1 media [RPMI (Invitrogen) containing 
0.2% FBS, 1:5.000 ITS (Invitrogen), 100 ng/ml Activin A, and 50 ng/ml WNT3a (R&D 
Systems)].  Clusters from two wells were combined into one well and distributed into low 
attachment plates in 5.5 ml d1 media.  Subsequently, cell clusters were differentiated into β-





















Generation of TgBAC(pdx1:EGFP)bns13, TgBAC(pdx1:luciferase)bns17, TgBAC(arxa:Cre)bns250 
and Tg(ins:loxP-Eco.NfsB-mCherry-loxP-luciferase)bns152 lines 
To generate the pdx1 and arx bacterial artificial chromosome (BAC) constructs, we used the 
BAC clones DKEY-244H6 containing 200 kb of the pdx1 locus and CH73-369P3 containing 
200 kb of the arx locus.  All recombineering steps were performed as described in (Bussmann 
et al. 2011) with the modification that we removed the Kanamycin cassette with a flipase for 
the arxaBAC:Cre construct.  The following homology arms were used to generate the targeting 
PCR products of the EGFP_Kan, Luc2_Kan and Cre_Kan cassettes:  
pdx1-HA1: 5’-ggcgctggctcatgtgctcgtgtacggcacggtttccccggtctatggca-3’ 
and pdx1-HA2: 5’-aatcgggaagagcattactatccgcctaaccacctgtacaaggactcttg-3’;  
arxa-HA1: 5’-tgcgagagagagtaacagtcacccactcgagcacgactgaggacgataca-‘3 
and arxa-HA2: 5’-ttgcttttacattcgctccgatcgcggctatcgtcgtcgtactgactgct-‘3. 
The TgBAC(pdx1:EGFP)bns13 and  TgBAC(pdx1:luciferase)bns17 lines exhibit expression in cell 
types known to express pdx1 including β-cells and ductal cells (Ohlsson et al. 1993; Kritzik et 
al. 1999).  We hypothesize that due to the fast transitory stage of the pancreatic endoderm in 
zebrafish, the TgBAC(pdx1:EGFP)bns13 and TgBAC(pdx1:luciferase)bns17 lines do not clearly label 
the pancreatic endoderm.  Another explanation would be that the regulatory elements driving 
pdx1 expression in the pancreatic endoderm might not be present in the DKEY-244H6.  To 
generate the Tg(ins:loxP-Eco.NfsB-mCherry-loxP-luciferase)bns152 line, abbreviated as 
Tg(ins:mCherry), the loxP Eco.NfsB-mCherry loxP cassette was amplified by PCR and cloned 
downstream of the insulin promoter together with a 5’ beta-globin intron.  In a second cloning 
reaction, luciferase was amplified by PCR and cloned downstream of Eco.NfsB-mCherry loxP.  
Several founder fish were identified and analyzed.  All founder fish exhibited similar patterns 
of EGFP, Luciferase, Cre, or mCherry expression, ruling out effects related to the site of 
integration.  
 
Whole Mount in situ Hybridization 
Single in situ hybridizations were performed as described  (Thisse et al. 2008; Helker et al. 
2013). 
The following probes were synthesized: insulin (Milewski et al. 1998); pdx1 was amplified 
from cDNA of 24 hpf old embryos using the following primers pdx1-forward 5’- 
caggtagagcagaggtcctga -3’ and pdx1-reverse 5’- tcacatcactttaatgtttgtggtaa -3’.  The T7 
promoter was added to the 5’- end of the reverse primer in a second round of amplification. 
 
Luciferase assay and small molecule screening 
Homozygous TgBAC(pdx1:luciferase)bns17 animals were outcrossed to AB wild-types to collect 
large numbers of hemizygous embryos for experiments.  At 72 hpf, healthy larvae were selected 
and washed with egg water before distributing three larvae per well in 200 μl egg water in 96-
well plates.  Each compound was tested in duplicates.  Drugs were used at a concentration of 
10 μM in 1% DMSO.  After 48 h of treatment, the samples were incubated in Steady Glo 
(Promega) as described previously (Gut et al. 2013).  The bioluminescence signal was analyzed 
by FLUOstar Omega (BMG LABTECH).  Each well was normalized to the average of the 
DMSO wells in each plate. 
An up-regulation of 1.5-fold up in both replicates was assigned as the hit compound threshold.  



















compounds were not very stable and induction of the TgBAC(pdx1:luciferase) reporter at low 
concentrations was only achieved with freshly ordered compounds.  The following chemical 
libraries were used: LOPAC (Sigma-Aldrich), MicroSource Spectrum Collection, Prestwick 
Chemical Library, PKIS (Published Kinase Inhibitor Set), Selleckchem Kinase Inhibitory 
Library, Epigenetic Screening Library, Cayman and TimTec Natural Compound Library.  Data 
analysis was done using a custom script in the statistical language R.   
 
Glucose measurements  
After drug treatment, 3 replicates of 5 larvae per condition were homogenized and free glucose 
levels were determined using a glucose assay kit (BioVision) as described previously (Gut et 
al. 2013).  
 
qRT-PCR 
Total RNA from control and drug-treated MIN6 cells was extracted using a RNeasy Mini Kit 
(Qiagen).  Reverse transcription polymerase chain reaction (RT–PCR) was performed using a 
SuperScript III First-Strand Synthesis System (Invitrogen) according to manufacturer’s 
instructions.  qRT-PCR was carried out to quantify gene expression levels on a CFX connect 
Real-time System (Bio Rad) with the following Taqman probes:  Pdx1 Mm00435565_m1, Ins1 
Mm01950294_s1.  Each sample was normalized to the housekeeping probe Gapdh 
Mm99999915_g1. 
Total RNA of β-like cells was isolated using a High Pure RNA Isolation Kit (Roche) or Trizol 
(Invitrogen).  First strand reverse transcription was performed with 1.5 μg RNA using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche).  RT-qPCR was carried out in triplicates 
using the SYBR Green PCR Master Mix (Thermo Fisher) on a Bio-Rad LightCycler.  Results 
were normalized to GAPDH transcripts.  Primers used for RT-qPCR are listed in supplementay 
Table 3.  All reactions were performed with annealing at 60°C for 40 cycles.  For undetectable 
transcripts, the cycle number was set to 40 for comparisons. 
 
Confocal Microscopy  
Zebrafish larvae were mounted in 1% low melt agarose.  Egg water and agarose were 
supplemented with 19.2 mg/l Tricaine.  All fluorescent images were acquired using an upright 
Zeiss LSM 780, 800 or 880 Confocal microscope.  Maximum projection images were analyzed 
and generated using Imaris (Bitplane).   
 
Immunostaining  
Zebrafish larvae were immunostained according to (Lancman et al. 2013).  The following 
primary antibodies were used: Nkx6.1 (DSHB) and Pdx1 (gift from Chris Wright). 
 
Insulin secretion from mouse islets 
Pancreatic islets were isolated from 16- to 20-week-old C57BL/6J mice following LiberaseTL 
(Roche) infusion via the common bile duct to disrupt the pancreatic exocrine tissue and 
filtration to recover intact islets.  Islets were hand-picked and cultured overnight in RPMI1640 
supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin.  Islets were 
treated with 10 µM of the hit compounds for 12 h in RPMI1640 containing 0.2% BSA, 100 



















conducted in KRB buffer containing 4.6 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 17.7 mM NaHCO3, 10 mM HEPES, 117 mM NaCl and 0.2% BSA.  10 size-matched 
islets were pre-incubated for 1 h in KRB containing 3 mM glucose prior to collection of the 
supernatant from incubations with fresh KRB containing 3 mM and 15 mM glucose.  Insulin 
secretion was assessed with a Mouse Insulin ELISA kit (Alpco) following manufacturer’s 
protocol. 
 
Cell transfection and determination of [Ca2+] 
COS-1 cells were seeded in 96-well plates with white walls and transparent bottom and 
transfected with plasmids containing cDNA encoding a calcium-sensitive bioluminescent 
fusion protein consisting of aequorin and GFP (Baubet et al. 2000) as well as the indicated 
receptors using Lipofectamine 2000 (Life Technologies) following manufacturer’s instructions.  
48 h later, cells were loaded with 5 µM coelenterazine (Promega) in HBSS containing 1.8 mM 
calcium and 10 mM glucose for 2 h at 37°C.  Measurements were performed using a 
luminometric plate reader (Flexstation 3, Molecular Devices).  The area under each calcium 
transient was calculated using SoftMaxPro software and expressed as area under the curve 
(AUC). 
 
Glucose-stimulated insulin secretion of human islets 
Thirty human islets per well were handpicked under a light microscope into 6-well plates 
containing 2 ml of CMRL-1066 (ICN Biomedicals, Cosa Mesa, CA) supplemented with 10 
mM HEPES, 2 mM L-glutamine, 50 µg/ml Gentamicin, 20 µg/ml Ciprofloxacin, 10 mM 
nicotinamide, and 10% heat-inactivated human serum.  The islets were cultured for 24 h at 37°C 
with the addition of 10 µM HC Toxin (or DMSO-containing vehicle only) before assessment 
of glucose-stimulated insulin secretion (GSIS) in a dynamic perifusion system (PERI-4.2, 
Biorep Technologies, FL, USA).  In brief, the islets were transferred to a perifusion chamber 
and perifused with low (1.6 mM) and high (20 mM) glucose Krebs solution at a flow rate of 
100 µl/min at 37°C and collection of the perifusate in 1 min fractions.  After a 34 min 
stabilization period at low glucose, the islets were challenged with high glucose for 15 min and 
then perifused again with low glucose for 15 min.  Insulin was measured in the perifusate 
fractions with ELISA (Mercodia, Uppsala, Sweden) according to manufacturer’s instructions. 
 
Quantifications  
β-cell numbers: The average cell number counted in the islets of control DMSO treated larvae 
was set at 100 percent and the relative changes were calculated.  The pdx1 positive area was 
quantified by using the area measurement tool from ImageJ. 
 
Statistics 
Standard error of the mean and p-values using a 2-tailed t-test were calculated using Microsoft 
























pdx1 expression dynamics  
In order to generate reliable transgenic lines to monitor pdx1 expression, we chose a BAC 
(bacterial artificial chromosome) approach over the more commonly used approach of short 
promoter fragments.  This strategy has the clear advantage of having more, or even sometimes 
all, regulatory elements included in the transgene.  We selected a BAC containing 100 kb 
upstream and 100 kb downstream of pdx1 and replaced the ATG of pdx1 with a Luciferase 
cassette to allow a fast and quantitative readout of pdx1 expression levels (Fig. S1).  An 
additional BAC transgenic line was made by inserting an EGFP cassette to visualize pdx1 
expression at single cell resolution (Fig. S1).  As expected, we observed pdx1 reporter 
expression in insulin (ins) expressing β-cells at 120 hpf (hours post fertilization) (Fig. 1A, B, 
S1) and coexpression with endogenous Pdx1 (Fig. 1C).  To assess the TgBAC(pdx1:luciferase2) 
(hereafter referred to as TgBAC(pdx1:Luc2)) line, we measured pdx1 promoter activity over the 
time period of β-cell maturation, i.e., from 48-120 hpf.  Coincident with the increase in β-cell 
maturation, we observed an increase in pdx1 promoter activity (Fig. 1D).  Once β-cell 
maturation was achieved, pdx1 promoter activity decreased (Fig. 1D) and free glucose levels 
dropped (Fig. 1E) (Gut et al. 2013; Mullapudi et al. 2018).   
 
Whole organism screen for modulators of pdx1 expression 
It was recently shown that inhibiting Alk5 (aka Tgfβr1, Transforming growth factor beta 
receptor 1) in mammalian islets induces the expression of mature β-cell markers, including 
Pdx1 (Blum et al. 2014).  To test whether the TgBAC(pdx1:Luc2) line was indeed functional and 
responsive to known modulators of pdx1 expression, we treated 72 hpf TgBAC(pdx1:Luc2) larvae 
with pharmacological inhibitors of Alk5 for 48 hours followed by a luciferase assay.  Indeed, 
we observed a significant induction of transgene expression (Fig. 2A).  Thus, the response of 
our transgenic reporter to known modulators of pdx1 expression in mammals supports its use 
for the identification of novel compounds.  The luciferase signal of the TgBAC(pdx1:Luc2) 
reporter could be modulated by the level of promoter activity, or by the number of β-cells.  In 
order to test this latter hypothesis, we treated 72 hpf TgBAC(pdx1:Luc2) and TgBAC(pdx1:EGFP) 
larvae with a 𝛾-secretase inhibitor (LY411575) to induce secondary islet formation (Parsons et 
al. 2009; Ninov et al. 2012).  Indeed, we observed an increase in the luciferase signal 
concomitant with the induction of secondary islets (Fig. 2B).  To visualize whether secondary 
islets were also marked by the TgBAC(pdx1:EGFP) reporter, we analyzed the treated animals by 
confocal microscopy.  In DMSO treated control larvae, we did not observe any 
TgBAC(pdx1:EGFP) positive secondary islets.  However, in line with the observed increase in 
luciferase signal, we found EGFP positive cells along the pancreatic duct after treatment with 
the 𝛾-secretase inhibitor (Fig. 2C). 
Next, we designed a high throughput platform to screen for modulators of pdx1 expression.  We 
decided to use 72 hpf old larvae since metabolic organs are formed by this stage, and these 
animals are still small enough to be kept in 96 well plates.  Three 72 hpf TgBAC(pdx1:Luc2) 
larvae were transferred into each well of 96 well plates and treated in duplicates with small 
molecule libraries.  We decided to use 10 µM, a concentration commonly used in whole 
organism screens in zebrafish (Andersson et al. 2012; Gut et al. 2013; Tsuji et al. 2014; Gut et 



















inspection of the 96 well plates for signs of toxicity, followed by incubation with a long half-
life firefly luciferin to directly measure bioluminescence (Fig. 2D).  By screening 8,256 small 
molecules from diverse chemical libraries, we identified 9 that caused the upregulation of the 
pdx1 driven luciferase signal (Fig. 2E, Supplemental Table 1).   
Interestingly, among the hit molecules, we found two known regulators of β-cell biology:  SKF-
86055 and 2',3'-O-Isopropylideneadenosine (Supplemental Table 1).  While SKF-86055 
inhibits Alk5 and leads to an upregulation of Pdx1 expression (Blum et al. 2014), 2',3'-O-
Isopropylideneadenosine is an adenosine receptor agonist, which increases β-cell replication 
after β-cell ablation (Andersson et al. 2012).  In terms of the other hits, we did not further 
analyze the PI3K inhibitor due to its known function on the insulin signaling pathway; the 
MSK1 inhibitor was not commercially available; and the results of the EGFR inhibitor could 
not be confirmed when using a freshly ordered compound.  Dose response curves of the 4 
remaining compounds are shown in Fig. S3.  Another top hit, Chaulmoogric acid ethyl ester, 
has not been studied in the context of β-cell biology (Supplemental Table 1).  By analyzing the 
structure of Chaulmoogric acid (Fig. S2), we hypothesized that it could be an agonist for the 
fatty acid receptor GPR40.  Importantly, GPR40 is expressed by β-cells (Itoh et al. 2003), and 
its agonists have entered clinical trials for the treatment of diabetes (Poitout and Lin 2013).  To 
test this hypothesis, we measured GPR40 activation in COS-1 cells.  Following the addition of 
Chaulmoogric acid, we indeed found a dose-dependent activation of GPR40 (Fig.S4).  Overall, 
the identification of known modulators of β-cell mass and function further validates our 
screening strategy.   
 
HDAC inhibitors increase pancreatic endoderm at the expense of hepatic endoderm 
To analyze whether the hit compounds influence pancreatic endoderm development, we treated 
wild-type embryos from 5-24 hpf followed by in situ hybridization for pdx1 expression (Fig. 
3A).  We tested five compounds and found an increase of the pdx1 positive pancreatic endoderm 
area in the embryos treated with the HDAC inhibitors Scriptaid and VPA, as well as those 
treated with the Alk5 inhibitor (Fig. 3B-G).  Next, we treated Tg(sox17:EGFP) embryos with 
VPA and analyzed them by confocal microscopy and could indeed confirm the increase in the 
pancreatic endoderm area (Fig. 3H-J).  More strikingly, we found that the area of the hepatic 
endoderm appeared substantially decreased (Fig. 3H-I).   
 
Alk5 inhibition increases β-cell mass by transdifferentiation of -cells to β-cells 
To analyze whether the hit compounds cause an increase in β-cell mass, we treated Tg(ins:H2B-
GFP;ins:DsRed) larvae.  This strategy allows one to identify newly specified β-cells by the 
expression of the fast folding fluorophore GFP, while older β-cells will be labeled with GFP as 
well as with the slow folding fluorophore DsRed (Hesselson et al. 2009).  Even though we 
found no significant increase in β-cell number, there was a trend towards such an increase in 
larvae treated with the Alk5 inhibitor (Fig. 4A-G).  More strikingly, we observed newly 
specified β-cells (i. e., GFP + DsRed -) after Alk5 inhibition (Fig. 4F 4G, arrowheads).  Due to 
the close developmental relationship between - and β-cells, we hypothesized that the new β-
cells were -cell derived.  To test this hypothesis, we generated TgBAC(gcga:Cre) and 
TgBAC(gcga:CreERT2) lines to lineage trace -cells.  To our surprise, we found an even more 



















shown) than previously reported (Ye et al. 2015).  Therefore we decided to generate a 
TgBAC(arx:Cre) line to specifically label -cells (Fig. S5).  We crossed the TgBAC(arx:Cre) line 
to the Tg(insulin:loxP:mCherrySTOP:loxP:H2B-GFP) reporter line, in order to specifically 
label all -cell derived β-cells by the expression of H2B-GFP (Fig. 4 H-I).  By treating the 
double transgenic larvae with the Alk5 inhibitor, we found a significant increase in -cell-
derived β-cells (Fig.4 H-J).  In agreement with these findings, we observed an increase in 
bihormonal endocrine cells (Tg(gcg:EGFP)+ and Tg(ins:mCherry)+) after Alk5 inhibition 
(Fig.4 K-M).   
 
HDAC inhibitors increase pdx1 expression and decrease glucose levels 
β-cell differentiation can be examined in zebrafish by analyzing the formation of secondary 
islets following metabolic demand or Notch inhibition (Parsons et al. 2009; Ninov et al. 2013).  
To analyze whether the increase in pdx1 promoter driven luciferase activity arises from 
increased endocrine cell differentiation, we treated the pan-endocrine reporter line 
TgBAC(neuroD:EGFP) with the different HDAC inhibitors.  Blocking Notch signaling with the 
𝛾-secretase inhibitor DAPT leads to differentiation of endocrine cells along the pancreatic duct 
(Fig. S6, arrows) (Parsons et al. 2009; Ninov et al. 2012).  However, none of the HDAC 
inhibitors led to an increase in secondary islet formation (Fig. S6, arrows).   
Next, we evaluated whether HDAC inhibition could influence β-cell function directly.  We 
speculated that enhanced β-cell function (i. e., insulin secretion) would lead to a change in larval 
glucose levels.  By measuring glucose levels in whole larvae, we found that two out of the three 
HDAC inhibitors tested could reduce glucose levels (Fig. 5A).  These results indicate that 
HDAC inhibition regulates β-cell function.  To further evaluate whether HDAC inhibitors could 
reduce glucose levels in settings of hyperglycaemia, we treated larvae with the β-adrenergic 
agonist isoprenaline to induce a strong gluconeogenic response and elevate glucose levels (Fig. 
5B) (Gut et al. 2013).  Strikingly, the elevated levels of glucose by isoprenaline were completely 
reversed by co-administration with the HDAC inhibitors HC Toxin, Scriptaid and VPA (Fig. 
5B).  To analyze whether the HDAC inhibitors reduced glucose levels by inhibiting 
gluconeogenesis in the liver, we treated Tg(pck1:luciferase2) larvae.  For all three HDAC 
inhibitors, we observed a reduction in the luciferase signal (Fig. 5C).  To ensure that the glucose 
level lowering effect was not caused by general toxicity to the animals or their liver, we 
analyzed the general health of the animals as well as liver morphology and did not observe any 
obvious phenotypes after treatment with the HDAC inhibitors (Fig. S7).    
 
The glucose lowering effect of HDAC inhibition depends on insulin and Pdx1 
To determine whether the glucose level lowering effect of the HDAC inhibitors depended on 
insulin action, we used insulin mutants.  Due to the lack of insulin, these mutant larvae exhibit 
elevated glucose levels.  Therefore, any reduction in glucose levels in this model would indicate 
that the glucose lowering effect is independent of insulin.  Among the three HDAC inhibitors 
analyzed, none of them caused a reduction in glucose levels in the absence of insulin (Fig. 5D), 
indicating that HC Toxin and Scriptaid enhance β-cell functionality in vivo in an insulin 
dependent manner.  To further investigate the most promising compound, HC Toxin, and 
analyze whether its mechanism of action depended on Pdx1 itself, we used pdx1 mutants 



















the presence of β-cells (Kimmel et al. 2015).  We treated pdx1 mutants with the HDAC inhibitor 
HC Toxin and strikingly observed reduced glucose levels in heterozygous, but not homozygous 
mutant animals (Fig. 5E).  Together these experiments show that the glucose level lowering 
effect of HC Toxin depends on Pdx1 and insulin. 
 
HDAC inhibition stimulates the expression of β-cell differentiation markers and the 
function of mouse and human β-cells 
To determine whether the induction of Pdx1 expression by HDAC inhibition was conserved 
across species, we used the murine β-cell cell line MIN6, treated the cells with HC Toxin and 
performed RT-qPCR for Pdx1 (Fig. 6A) and Ins1 (Fig. 6B) expression.  We found an 
upregulation of Pdx1 and Ins1 expression after treatment with HC Toxin (Fig. 6A, B).  
To further investigate the effect of HC Toxin on β-cell differentiation, we turned to a culture 
system to model human pancreatic β-cell development (Fig. 6C).  We used a previously 
published differentiation protocol (Russ et al. 2015) to efficiently generate insulin-producing 
cells from human iPSCs, and exposed the cells to HC Toxin during the last step of 
differentiation.  Specifically, iPSCs undergoing differentiation were treated with HC Toxin for 
24 h on day 18, and subsequently analyzed by RT-qPCR at day 21 (Fig. 6C, D).  Strikingly, we 
observed an increase in the expression levels of key β-cell transcription factor genes including 
PDX1, NKX2.2 and NEUROD1 as well as INS after exposure to HC Toxin, suggesting a 
conserved role for HC Toxin in human β-cell differentiation (Fig. 6D).  In addition, the 
transcript levels of the mature human β-cell transcription factor gene MAFB was robustly 
induced in cells treated with HC Toxin (Fig. 6D).  Taken together, these results indicate that 
HDAC inhibition can efficiently induce the expression of β-cell differentiation markers in vitro. 
In order to test whether HC Toxin treatment can also modulate the function of primary 
mammalian β-cells, we tested HC Toxin in a glucose stimulated insulin secretion (GSIS) assay 
in isolated C57BL/6J mouse islets.  We isolated islets from wild-type adult mice and cultured 
them overnight in the presence of the HDAC inhibitors.  On the next day, we performed a GSIS 
assay and measured released insulin by ELISA.  Treatment of islets with HC Toxin was 
associated with a higher GSIS compared to control islets (Fig. 7A).  Given the importance of 
translating fish and murine model results into a human assay system, we next wanted to test 
whether the compounds identified in the zebrafish screen would work in human samples.  
Therefore, an islet perifusion assay was used to assess whether HC Toxin treatment caused an 
increase in GSIS in freshly isolated human islets.  Details about the human donors can be found 
in Supplemental Table 2.  In response to glucose, HC Toxin treated human islets showed 
significantly increased insulin release compared to DMSO treated controls (Fig. 7B).  Thus, 
consistent with the findings with mouse islets, treatment of human islets with HC Toxin 
enhanced β-cell function via insulin secretion.  These data show that compounds identified in 




Small molecule screening in animals like zebrafish combines the high-throughput rate of a 
cellular system with the complex inter-organ physiology of an intact animal (MacRae and 
Peterson 2015; Gut et al. 2017).  Here we describe a novel approach for fast and reliable in vivo 



















BAC to generate the reporter we could recapitulate pdx1 expression in cell types known to 
express this gene including β-cells and ductal cells (Ohlsson et al. 1993; Kritzik et al. 1999).  
This observation is in line with the concept that transgenic lines made with BACs recapitulate 
the endogenous expression more closely compared to those made with short promoter 
fragments.  Besides the validation of our reporter with compounds known to induce Pdx1 
expression in human tissue, we identified compounds with well-known roles in regulating β-
cell biology, thus validating the strategy.  One example is Chaulmoogric acid which we 
identified as a novel agonist for the fatty acid receptor GPR40.  GPR40 is abundantly expressed 
by β-cells and it has been shown that the activation of GPR40 by agonists amplifies GSIS (Itoh 
et al. 2003).  In addition, we identified compounds which have not been implicated in the 
context of pancreas and β-cell development.  By using our screening strategy, we identified 
nine hit molecules which positively modulate the pdx1 reporter.  Among the hit molecules, we 
identified three structurally diverse HDAC inhibitors: HC Toxin (cyclic peptide HDAC 
inhibitor), Scriptaid (hydroxamic acid HDAC inhibitor) and VPA (aliphatic acid HDAC 
inhibitor).  Even though several HDAC inhibitors were screened in our assay, only VPA, HC 
Toxin, Scriptaid and TSA (data not shown) could reproducibly induce the pdx1 reporter.  In 
addition, the two benzamide HDAC inhibitors, MS-275 and CI-994, induced the pdx1 reporter, 
but only at 50 µM (data not shown).   
TSA and VPA have recently been shown to enhance the pool of the proendocrine lineage 
(Haumaitre et al. 2009).  This observation is in line with our results showing that VPA increases 
pancreatic endoderm size which subsequently leads to an increase in the proendocrine lineage.  
In addition, work from Noel et al. (2008) showed a reduced liver size in hdac1 mutants, which 
is in line with our observations showing that VPA treatment decreased the area of the hepatic 
endoderm.  It will be interesting to analyze the pancreatic endoderm in the hdac1 mutants.  In 
zebrafish, VPA treatment has been shown to disrupt the clustering of endocrine cells (Li et al. 
2016).  However, this disruption could be caused by the early and long treatment period used 
which included gastrulation (5 to 72 hpf).  HC Toxin and Scriptaid have recently been shown 
to enhance glucose uptake and metabolism in mouse skeletal muscle (Tan et al. 2015; Gaur et 
al. 2017).  However, these studies only focused on mechanisms downstream of insulin.  It has 
also been shown that HDAC inhibition protects β-cells from cytokine induced apoptosis 
(Larsen et al. 2007).  Since Pdx1 haploinsufficiency also leads to β-cell apoptosis (Johnson et 
al. 2003), it would be interesting to test whether increase of Pdx1 expression by HDAC 
inhibition protects β-cells from cytokine induced apoptosis.  In addition to these published 
observations, our data clearly show that Scriptaid and HC Toxin regulate glucose homeostasis 
by modulating β-cell function.  The reduction in whole body glucose levels could be due to an 
increase in insulin secretion by β-cells, increased glucose uptake by target tissues such as 
muscle and reduced gluconeogenesis in the liver.  Even though VPA caused only a mild effect 
in our assays compared to Scriptaid and HC Toxin, data obtained from human patients treated 
with VPA show increased postprandial insulin levels (Luef et al. 2002), confirming our 
observations. 
HDACs alter chromatin structure and transcriptional activity by removing lysine acetylation on 
histones (Seto et al. 2014).  However, several non-histone proteins are also regulated by lysine 
acetylation (Seto et al. 2014).  Therefore, it is not clear whether the mechanism of action of 
VPA, HC Toxin and Scriptaid is based on epigenetic regulation by chromatin or on 



















shown that HDAC inhibitors have anti-proliferative effects on cancer cells, and several of them 
are now used in clinical trials (West et al. 2014).  However, a clear mechanism of action has 
not yet been attained.  Recently, it has been shown that protein acetylation can alter the 
metabolism of the cell (Zhao et al. 2010), which can be achieved by post-translational 
modification of non-histone cytoplasmic and mitochondrial proteins (Anderson et al. 2012; 
Kim et al. 2006).  In fact, several HDACs have been localized in the cytoplasm and 
mitochondria (Bakin et al. 2004; Drazic et al. 2016; Herr et al. 2018).  On a functional level, it 
has been shown that treatment with HDAC inhibitors causes a rapid increase in mitochondrial 
activity, arguing against a regulation at the level of the chromatin (Becker et al. 2018).  The 
observation of an increase in GSIS as early as five hours after treatment (data not shown) 
indicates that this response is independent of epigenetic regulation or cell proliferation.  Recent 
work has been reported that the deletion of HDAC3 in β-cells led to glucose intolerance (Chen 
et al. 2016).  However, simultaneously, another group reported that the deletion of HDAC3 in 
β-cells improved glucose tolerance (Remsberg et al. 2017).  Of interest, Remsberg et al. (2017) 
also showed that a PDX1 motif is enriched under HDAC3 binding peaks.  Together with our 
work, these finding lead us to speculate that HDACs regulate Pdx1 expression to modulate β-
cell function. 
A new hope for the treatment of type 1 diabetes is the transplantation of stem cell derived β-
cells.  Recently, several groups have reported the differentiation of β-like-cells from stem cells 
(Pagliuca et al. 2014; Rezania et al. 2014; Russ et al. 2015).  However, the efficiency in 
generating β-like-cells is still low and varies between groups.  So far, HDAC inhibitors have 
not been used in β–cell differentiation protocols.  Our findings indicate that the addition of HC 
Toxin can efficiently induce the expression of differentiation markers in vitro, not only 
illustrating the value of our screen, but also adding another modulator to further optimize 
protocols for β-like-cell generation in vitro.  Notably, the Alk5 inhibitor which we identified in 
our zebrafish screen, has been shown to upregulate Pdx1 expression in human islets (Blum et 
al. 2014), and it is already in use in β-cell differentiation protocols (Pagliuca et al. 2014; Rezania 
et al. 2014; Russ et al. 2015).   
Recent work has highlighted the potential of -cells as a source for new β-cells during 
regeneration (Thorel et al. 2010; Courtney et al. 2013).  Follow up studies reported GABA as 
a possible signal driving  to β-cell transdifferentiation (Ben-Othman et al. 2017; Li et al. 
2017).  However, independent studies have now shown that the use of the Gcg promoter for 
lineage tracing might have led to a misinterpretation of the results (van der Meulen et al. 2018; 
Ackermann et al. 2018).  In agreement with this concern, we observed intensive β-cell labeling 
with our newly generated TgBAC(gcga:Cre) and TgBAC(gcga:CreERT2) lines (data not shown), 
which might be caused by the expression of gcga by β-cells (Tarifeno-Saldivia et al. 2017).  
Since it has been shown that arxa is specifically expressed in mature  but not β-cells (Tarifeno-
Saldivia et al. 2017), we decided to generate a TgBAC(arxa:Cre) line to specifically label -cells.  
Our results highlight a novel role for TGF-β signaling during  to β-cell transdifferentiation.  
The potential role of TGF-β signaling in -cells is in line with recent work profiling different 
endocrine cell types and showing the specific expression of the TGF-β receptor 2 gene in -
cells (Tarifeno-Saldivia et al. 2017).  Further work is needed to elucidate how TGF-β signaling 
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Fig.1 pdx1 expression in β- and ductal cells 
A) Visualization of TgBAC(pdx1:EGFP) expression.  A 200 kb pdx1 BAC drives EGFP 
expression specifically in the pancreatic islet (arrows).  Pancreatic β-cell specific reporter signal 
in Tg(ins:Kaede) larva is shown for comparison.  B) Confocal images of the pancreatic islet of 
a 120 hpf TgBAC(pdx1:EGFP); Tg(ins:DsRed) larva showing β-cell TgBAC(pdx1:EGFP) 
expression.  C) Confocal images of the pancreas of a 120 hpf TgBAC(pdx1:EGFP) larva 
immunostained for GFP, Pdx1 and Nkx6.1 showing colocalisation of TgBAC(pdx1:EGFP) 
expression with endogenous Pdx1.  D) Dynamics of pdx1 promoter activity over time as 
measured by TgBAC(pdx1:luciferase) activity.  The TgBAC(pdx1:luciferase) signal starts to 
become detectable at 72 hpf, peaks at 120 hpf and decreases by144 hpf.  E) At the peak of the 
TgBAC(pdx1:luciferase) signal, whole body free glucose levels start to decrease, indicating β-
cell function.  AU, arbitrary units;  p-values: * for p≤0.05, ** for p≤0.01, and *** for p≤0.001.  























Fig. 2 Whole organism screen for modulators of pdx1 expression 
A) 48 hour treatment of 72 hpf TgBAC(pdx1:Luc2) larvae with two TGF-β inhibitors which 
increase pdx1 mRNA levels in human islets leads to an increase in Luciferase activity.  B) 48 
hour treatment of 72 hpf TgBAC(pdx1:Luc2) larvae with the γ-secretase inhibitor LY411575, 
which leads to increased differentiation of β-cells, leads to an increases in Luciferase activity.  
C) 96 hour treatment of 72 hpf TgBAC(pdx1:EGFP) larvae with LY411575 leads to secondary 
islet formation as marked by TgBAC(pdx1:EGFP) expression (arrows).  D) Establishment of high 
throughput screening pipeline.  Mating wild-type zebrafish with homozygous 
TgBAC(pdx1:Luc2) reporter zebrafish generates clutches of 100% hemiozygous embryos.  At 72 
hpf, 3 larvae were transferred to each well of a 96 well plate and incubated for 48 hours with a 
specific compound at 10 µM.  At 120 hpf, each plate was incubated with long half-life luciferin 
and the bioluminescence intensity of each well measured in a standard plate reader.  E) Results 
of the primary screen.  Differential pdx1 promoter driven luciferase activity by small molecules 
of both duplicates is shown.  A total of 8,256 compounds from nine bioactive small molecule 
libraries were screened in duplicate.  Each axis represents the levels of pdx1 reporter expression 
fold change from one of the duplicates.  Dashed orange lines indicate 1.5-fold change.  Red 
dots, negative control (1% DMSO); black dots, small molecules.  (1) XL147; (2) SKF-86055; 
(3) Chaulmoogric ethyl ester; (4) VPA; (5) HC Toxin; (6) SB-736290; (7) PD168493; (8) 
Scriptaid; (9) 2',3'-O-Isopropylideneadenosine.  p-values: * for p≤0.05, ** for p≤0.01, and *** 























Fig. 3 HDAC inhibitor VPA increases pancreatic endoderm at the expense of hepatic 
endoderm 
A) Schematic of the experimental set up.  B-G) in situ hybridization on 24 hpf embryos showing 
pdx1 expression.  H) Scriptaid, VPA and Alk5i treatment lead to an increase in the pdx1 positive 
area.  I-K) Confocal pictures of 32 hpf Tg(sox17:EGFP) embryos treated with DMSO (I) as 
control or VPA (J).  K) VPA treatment leads to an increase in pancreatic endoderm area.  p-























Fig. 4 Alk5 inhibition increases β-cell mass by transdifferentiation of -cells to β-cells 
Confocal pictures of 120 hpf Tg(ins:H2B-GFP;ins:DsRed) larvae used to count β-cells.  
Tg(ins:H2B-GFP;ins:dsRED) larvae treated with DMSO (A), Scriptaid (B), HC Toxin (C), 
VPA (D), Chaulmoogric acid (E), or Alk5i (F) from 72-120 hpf.  Newly differentiated β-cells, 
labelled by H2B-GFP expression but negative for DsRed expression, are marked by 
arrowheads.  G) None of the treatments leads to a significant increase in total β-cell numbers.  
Alk5 inhibition leads to an increase of newly differentiated β-cells.  H-I) Confocal pictures of 
120 hpf TgBAC(arx:Cre); Tg(insulin:loxP:mCherrySTOP:loxP:H2B-GFP) larvae used to count 
-cell derived β-cells (arrowheads).  J) Alk5 inhibition leads to an increased number of H2B-
EGFP positive β-cells.  K-L) Confocal pictures of 120 hpf Tg(gcg:EGFP); Tg(insulin:mCherry) 
larvae used to count bihormonal endocrine cells (arrowheads).  M) Alk5 inhibition leads to an 
increased number of bihormonal endocrine cells.  p-values: * for p≤0.05, ** for p≤0.01, and 






















Fig. 5 Upregulation of pdx1 expression positively regulates β-cell function 
A) Scatter plot of the hits of the primary screen comparing activation of the TgBAC(pdx1:Luc2)  
reporter to glucose levels.  B) Glucose levels after treatment with hit compounds under 
hyperglycaemic conditions (isoprenaline-stimulated gluconeogenesis).  C) Treatment of the 
Tg(pck1:Luc2) line from 72-120 hpf with the three HDAC inhibitors leads to a reduction in 
Luciferase activity.  D) Glucose levels in insulin mutants treated with the three HDAC 
inhibitors.  E) Glucose levels in pdx1 heterozygous and homozygous mutant animals.  p-values:  























Fig. 6 HC Toxin induces the expression of β-cell differentiation markers in vitro 
A) qRT-PCR of Pdx1 mRNA expression levels in MIN6 cells treated with HC Toxin for 24 h.  
HC Toxin induces Pdx1 expression.  B) qRT-PCR of Insulin1 (Ins1) mRNA expression levels 
in MIN6 cells treated with HC Toxin for 24 h.  HC Toxin induces Ins1 expression.  C) 
Schematic representation of the differentiation protocol of iPSCs into β-like cells.  Cells were 
treated with HC Toxin for 24 h at day (D)18 of differentiation.  D) RT-qPCR analysis of 
selected gene expression levels at D0 (undifferentiated iPSCs), D21 (differentiated cells) and 
D21 HC (differentiated cells following treatment with HC Toxin), values are average ± SE; *, 























Fig. 7 HC Toxin positively regulates β-cell function in primary mouse and human β-cells 
A) Insulin levels from wild-type mouse islets treated with DMSO, Scriptaid, HC Toxin, VPA 
for 16 h in a static GSIS assay.  HC Toxin increases GSIS.  B) Insulin levels from human donor 
islets incubated for 24 h with DMSO and HC Toxin in a perfusion assay.  HC Toxin increases 





























































Fig. S1 Generation and validation of the TgBAC(pdx1:EGFP) reporter line 
A) BAC engineering used to generate TgBAC(pdx1:EGFP) and TgBAC(pdx1:Luc2).  The 200 kb
BAC DKEY-244H6 was engineered to carry an EGFP or Luciferase downstream of the pdx1 
ATG.  To enhance the frequency of insertion into the genome, we added tol2 arms on the 
backbone of the BAC.  B) in situ hybridization on 120 hpf zebrafish larvae for insulin (ins) 
expression.  C) in situ hybridization on 120 hpf zebrafish larvae for pdx1 expression.  D) 
Single confocal planes of the pancreatic islet of a 120 hpf TgBAC(pdx1:EGFP); Tg(ins:DsRed) 
larva showing β-cell specific TgBAC(pdx1:EGFP) expression.  E) Confocal images of the 
pancreas of a 120 hpf TgBAC(pdx1:EGFP); Tg(Tp1bglob:H2BmCherry) larva showing 
TgBAC(pdx1:EGFP) expression in the pancreatic duct.  Scale bars: B, 100 µm; C, 100 µm; D, 5 
µm; E, 15 µm. 






























Fig. S2 Structure of the hit molecules identified in the primary screen 
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Fig. S3 Dose response curves 
Dose response curves with freshly ordered Scriptaid, HC Toxin, VPA and Chaulmoogric 
ethyl ester show activation of the TgBAC(pdx1:Luc2) reporter.  Treatment of Chaulmoogric 
acid ethyl ester at 20 µM leads to the death of the larvae.  p-values: * for p≤0.05, ** for 
p≤0.01, and *** for p≤0.001. 


















































Fig. S4 Pharmacology of Chaulmoogric acid 
Measurement of GPR40 activation in cells heterologously expressing human GPR40 and an 
intracellular calcium sensitive probe (see methods) after addition of palmitic acid or 
Chaulmoogric acid.  Chaulmoogric acid activates GPR40.  Dose response curve of 
Chaulmoogric acid compared to palmitic acid.  No calcium traces are detected in non-
transfected cells.  AUC, area under the curve. 





































































Fig. S5 Validation of the TgBAC(arx:Cre) reporter line 
Confocal picture of a 120 hpf TgBAC(arx:Cre); Tg(ubb:loxP:CFP:loxP:H2B-GFP) larva 
immunostained for Glucagon and Insulin showing Cre recombination in -cells.  Glucagon 
expressing -cells are labeled by the TgBAC(arx:Cre) while Insulin expressing β-cells are not 
labelled.  p-values: * for p≤0.05, ** for p≤0.01, and *** for p≤0.001.  Scale bar: 3 µm 










































Fig. S6 Hit molecules do not induce secondary islet formation 
Animals from the pan-endocrine reporter line TgBAC(neuroD:EGFP) were treated with the different HDAC 
inhibitors VPA, HC Toxin and Scriptaid as well as the positive control DAPT for 96 hours starting at 72 
hpf.  Arrows point to secondary islets.  Scale bar: 20 µm. 









































Fig. S7 Hits compounds do not show signs of toxicity 
Treatment with HC Toxin, Scriptaid or VPA does not appear to affect the general health of the 
animals or induce liver toxicity.  Animals treated for 48 hours starting at 72 hpf.  Scale bars: 100 µm. 





















Table S1 Drugs identified to modulate pdx1 expression in zebrafish larvae.  Replicate 1 and replicate 2 represent the levels of pdx1 reporter
expression fold change.   





















replicate 1 replicate 2 name function library
3,4 3,22 S1118; XL147 PI3K inhibitor Kinase library; Selleckchem
2,05 2,56
CHAULMOOGRIC ACID, 
ETHYL ESTER fatty acid, GPR40 agonist Spectrum Collection, Microsource
2,73 2,8 SKF-86055 Alk5 inhibitor PKIS
1,93 1,79 Valproic acid HDAC inhibitor Epigenetic Screening Library, Cayman
1,76 1,89 HC Toxin HDAC inhibitor Epigenetic Screening Library, Cayman
1,66 1,73 SB-736290 MSK1 inhibitor PKIS
1,61 1,51 S7039; PD168393 EGFR inhibitor Kinase library; Selleckchem
1,51 1,5
2',3'-O-
Isopropylideneadenosine adenosine receptor agonist Natural Compounds; TimTech
1,51 1,5 Scriptaid HDAC inhibitor Epigenetic Screening Library, Cayman
Donor # Age Sex BMI (kg/m2) HbA1c
1 64 F 23 5,8
2 61 M 37 6,1
3 34 M 26,3 5,3
4 66 F 25,7 5,7
5 72 F 22,7 5,5
6 77 M 27,4 5,6
7 56 F 24,2 5,7
8 70 M 23,4 5,8
9 62 M 24,7 5,4
10 55 F 27 5,5
11 67 F 23,7 5,6
12 65 M 23,1 5,6
Table S2 Characteristics of human pancreatic islet donors.























































Table S3 Primers for RT-qPCR



































MIN6 Pdx1 21,86 22,36 21,16 20,37 
MIN6 Ins1 15,61 16,00 21,16 20,37 
iPSC PDX1 21,91 22,09 19,88 19,86 
iPSC NKX6.1 21,70 21,87 19,88 19,86 
iPSC NEUROD1 22,45 22,98 19,88 19,86 
iPSC INS 18,47 18,84 21,59 21,48 
iPSC SST 18,74 19,42 21,59 21,48 
iPSC NKX2.2 23,11 23,41 20,69 20,62 
iPSC ISL-1 23,85 24,19 20,13 20,01 
iPSC GCG 18,52 19,31 20,13 20,01 
iPSC PCSK1 23,9 24,2 20,34 20,27 
iPSC MAFB 23,14 23,3 20,34 20,27 
Table S4 Ct values for RT-qPCR
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